Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging Alphaviruses

PLoS Pathogens

Volumn 11, Issue 12, 2015, Pages

  Sali, Tina M ^a   Pryke, Kara M ^a   Abraham, Jinu ^a   Liu, Andrew ^a   Archer, Iris ^a,b   Broeckel, Rebecca ^a,b   Staverosky, Julia A ^a   Smith, Jessica L ^a   Al Shammari, Ahmed ^a,c   Amsler, Lisi ^a,b   Sheridan, Kayla ^d   Nilsen, Aaron ^d   Streblow, Daniel N ^a,b   DeFilippis, Victor R ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF BAGHDAD   (Iraq)

^d PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 CHLORO 6 FLUOROBENZYL)N (FURAN 2 YLMETHYL) 3 OXO 3,4 DIHYDRO 2H BENZO[B][1,4]THIAZINE 6 CARBOXAMIDE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AMIDE; CYCLIC GMP; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; LENTIVIRUS VECTOR; MESSENGER RNA; STAT1 PROTEIN; STING RECEPTOR AGONIST; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; VADIMEZAN; 4-(2-CHLORO-6-FLUOROBENZYL)-N-(FURAN-2-YLMETHYL)-3-OXO-3,4-DIHYDRO-2H-BENZO(B)(1,4)THIAZINE-6-CARBOXAMIDE; ANTIVIRUS AGENT; MEMBRANE PROTEIN; MPYS PROTEIN, HUMAN; MPYS PROTEIN, MOUSE; THIAZINE DERIVATIVE;

ALPHAVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CHIKUNGUNYA VIRUS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; GENE EXPRESSION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INNATE IMMUNITY; LUCIFERASE ASSAY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN PURIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINDBIS VIRUS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; AGONISTS; ALPHAVIRUS INFECTION; ANIMAL; C57BL MOUSE; CELL CULTURE; CHIKUNGUNYA; DRUG EFFECTS; HIGH THROUGHPUT SCREENING; IMMUNOLOGY; SIGNAL TRANSDUCTION;

ALPHAVIRUS; ALPHAVIRUS INFECTIONS; ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOBLOTTING; INTERFERON REGULATORY FACTOR-3; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THIAZINES;

EID: 84953205267     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005324     Document Type: Article

References (122)

1. Broz P, Monack DM, Newly described pattern recognition receptors team up against intracellular pathogens. Nature Publishing Group. 2013;13: 551–565. doi: 10.1038/nri3479
2. Es-Saad S, Tremblay N, Baril M, Lamarre D, Regulators of innate immunity as novel targets for panviral therapeutics. Current Opinion in Virology. 2012;2: 622–628. doi: 10.1016/j.coviro.2012.08.009 23017246
3. Sharma S, tenOever BR, Grandvaux N, Zhou G-P, Lin R, Hiscott J, Triggering the interferon antiviral response through an IKK-related pathway. Science. American Association for the Advancement of Science; 2003;300: 1148–1151. doi: 10.1126/science.1081315
4. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. American Association for the Advancement of Science; 2003;301: 640–643. doi: 10.1126/science.1087262
5. Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T, TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol. 2003;4: 161–167. doi: 10.1038/ni886 12539043
6. Xu L-G, Wang Y-Y, Han K-J, Li L-Y, Zhai Z, Shu H-B, VISA is an adapter protein required for virus-triggered IFN-beta signaling. Molecular Cell. 2005;19: 727–740. doi: 10.1016/j.molcel.2005.08.014 16153868
7. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol. 2005;6: 981–988. doi: 10.1038/ni1243 16127453
8. Seth RB, Sun L, Ea C-K, Chen ZJ, Identification and Characterization of MAVS, a Mitochondrial Antiviral Signaling Protein that Activates NF-κB and IRF3. Cell. 2005;122: 669–682. doi: 10.1016/j.cell.2005.08.012 16125763
9. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature. 2005;437: 1167–1172. doi: 10.1038/nature04193 16177806
10. Ishikawa H, Barber GN, STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455: 674–678. doi: 10.1038/nature07317 18724357
11. Zhong B, Yang Y, Li S, Wang Y-Y, Li Y, Diao F, et al. The Adaptor Protein MITA Links Virus-Sensing Receptors to IRF3 Transcription Factor Activation. Immunity. Elsevier Inc; 2008;29: 538–550. doi: 10.1016/j.immuni.2008.09.003
12. Sun W, Li Y, Chen L, Chen H, You F, Zhou X, et al. ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization. Proc Natl Acad Sci U S A. National Acad Sciences; 2009;106: 8653–8658. doi: 10.1073/pnas.0900850106
13. Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature. Nature Publishing Group; 2012;478: 515–518. doi: 10.1038/nature10429
14. Sun L, Wu J, Du F, Chen X, Chen ZJ, Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway. Science. 2013;339: 786–791. doi: 10.1126/science.1232458 23258413
15. Wu J, Sun L, Chen X, Du F, Shi H, Chen C, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science. 2013;339: 826–830. doi: 10.1126/science.1229963 23258412
16. Unterholzner L, Keating SE, Baran M, Horan KA, Jensen SB, Sharma S, et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol. 2010;11: 1004. doi: 10.1038/ni.1932
17. Stavrou S, Blouch K, Kotla S, Bass A, Ross SR, Nucleic Acid Recognition Orchestrates the Anti-Viral Response to Retroviruses. Cell Host and Microbe. Elsevier Inc; 2015;17: 478–488. doi: 10.1016/j.chom.2015.02.021
18. Defilippis VR, Alvarado D, Sali T, Rothenburg S, Früh K, Human cytomegalovirus induces the interferon response via the DNA sensor ZBP1. Journal of Virology. American Society for Microbiology; 2010;84: 585–598. doi: 10.1128/JVI.01748-09
19. Ireton RC, Gale M, Pushing to a cure by harnessing innate immunity against hepatitis C virus. ANTIVIRAL RESEARCH. 2014;108: 156–164. doi: 10.1016/j.antiviral.2014.05.012 24907428
20. Patel DA, Patel AC, Nolan WC, Zhang Y, Holtzman MJ, High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery. PLoS ONE. 2012. doi: 10.1371/journal.pone.0036594.t002
21. Wong JP, Christopher ME, Viswanathan S, Karpoff N, Dai X, Das D, et al. Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine. 2009;27: 3481–3483. doi: 10.1016/j.vaccine.2009.01.048 19200852
22. Silin DS, Lyubomska OV, Ershov FI, Frolov VM, Kutsyna GA, Synthetic and natural immunomodulators acting as interferon inducers. Curr Pharm Des. 2009;15: 1238–1247. 19355963
23. Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A, et al. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology. Wiley Subscription Services, Inc., A Wiley Company; 2007;46: 1769–1778. doi: 10.1002/hep.21897
24. Isogawa M, Robek MD, Furuichi Y, Chisari FV, Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. Journal of Virology. 2005;79: 7269–7272. doi: 10.1128/JVI.79.11.7269-7272.2005 15890966
25. Svensson A, Bellner L, Magnusson M, Eriksson K, Role of IFN-alpha/beta signaling in the prevention of genital herpes virus type 2 infection. J Reprod Immunol. 2007;74: 114–123. doi: 10.1016/j.jri.2006.09.002 17092567
26. Maisonneuve C, Bertholet S, Philpott DJ, De Gregorio E, Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci U S A. 2014;111: 12294–12299. doi: 10.1073/pnas.1400478111 25136133
27. Goulet M-L, Olagnier D, Xu Z, Paz S, Belgnaoui SM, Lafferty EI, et al. Systems Analysis of a RIG-I Agonist Inducing Broad Spectrum Inhibition of Virus Infectivity. PLoS Pathog. 2013;9: e1003298. 23633948
28. Olagnier D, Scholte FEM, Chiang C, Albulescu IC, Nichols C, He Z, et al. Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response. Journal of Virology. 2014;88: 4180–4194. doi: 10.1128/JVI.03114-13 24478443
29. Kramer MJ, Cleeland R, Grunberg E, Antiviral activity of 10-carboxymethyl-9-acridanone. Antimicrobial Agents and Chemotherapy. 1976;9: 233–238. 1267425
30. Perera PY, Barber SA, Ching LM, Vogel SN, Activation of LPS-inducible genes by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid in primary murine macrophages. Dissection of signaling pathways leading to gene induction and tyrosine phosphorylation. The Journal of Immunology. 1994;153: 4684–4693. 7525711
31. Guo F, Han Y, Zhao X, Wang J, Liu F, Xu C, et al. STING agonists induce an innate antiviral immune response against hepatitis B virus. Antimicrobial Agents and Chemotherapy. 2014. doi: 10.1128/AAC.04321-14
32. Cheng G, Wang L-CS, Fridlender ZG, Cheng G-S, Chen B, Mangalmurti NS, et al. Pharmacologic activation of the innate immune system to prevent respiratory viral infections. Am J Respir Cell Mol Biol. 2011;45: 480–488. doi: 10.1165/rcmb.2010-0288OC 21148741
33. Shirey KA, Nhu QM, Yim KC, Roberts ZJ, Teijaro JR, Farber DL, et al. The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. Journal of Leukocyte Biology. Society for Leukocyte Biology; 2011;89: 351–357. doi: 10.1189/jlb.0410216
34. Tang CK, Aoshi T, Jounai N, Ito J, Ohata K, Kobiyama K, et al. The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant. PLoS ONE. Public Library of Science; 2013;8: e60038. doi: 10.1371/journal.pone.0060038
35. Blaauboer SM, Gabrielle VD, Jin L, MPYS/STING-mediated TNF-α, not type I IFN, is essential for the mucosal adjuvant activity of (3“-5”)-cyclic-di-guanosine-monophosphate in vivo. J Immunol. 2014;192: 492–502. doi: 10.4049/jimmunol.1301812 24307739
36. Wallace A, LaRosa DF, Kapoor V, Sun J, Cheng G, Jassar A, et al. The Vascular Disrupting Agent, DMXAA, Directly Activates Dendritic Cells through a MyD88-Independent Mechanism and Generates Antitumor Cytotoxic T Lymphocytes. Cancer Res. 2007;67: 7011–7019. doi: 10.1158/0008-5472.CAN-06-3757 17638914
37. Jassar AS, Activation of Tumor-Associated Macrophages by the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid Induces an Effective CD8+ T-Cell-Mediated Antitumor Immune Response in Murine Models of Lung Cancer and Mesothelioma. Cancer Res. 2005;65: 11752–11761. doi: 10.1158/0008-5472.CAN-05-1658 16357188
38. Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. The Authors; 2015; 1–14. doi: 10.1016/j.celrep.2015.04.031
39. Cavlar T, Deimling T, Ablasser A, Hopfner K-P, Hornung V, Species-specific detection of the antiviral small-molecule compound CMA by STING. The EMBO Journal. 2013;32: 1440–1450. doi: 10.1038/emboj.2013.86 23604073
40. Kim S, Li L, Maliga Z, Yin Q, Wu H, Mitchison TJ, Anticancer flavonoids are mouse-selective STING agonists. ACS Chem Biol. 2013;8: 1396–1401. doi: 10.1021/cb400264n 23683494
41. Conlon J, Burdette DL, Sharma S, Bhat N, Thompson M, Jiang Z, et al. Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid. The Journal of Immunology. 2013;190: 5216–5225. doi: 10.4049/jimmunol.1300097 23585680
42. Weaver SC, Winegar R, Manger ID, Forrester NL, Alphaviruses: Population genetics and determinants of emergence. ANTIVIRAL RESEARCH. Elsevier B.V; 2012; 1–16. doi: 10.1016/j.antiviral.2012.04.002
43. Johansson MA, Chikungunya on the move. Trends in Parasitology. Elsevier Ltd; 2015;31: 43–45. doi: 10.1016/j.pt.2014.12.008
44. Zehmer RB, Dean PB, Sudia WD, Calisher CH, Sather GE, Parker RL, Venezuelan equine encephalitis epidemic in Texas, 1971. Health Serv Rep. 1974;89: 278–282. 4151413
45. Go YY, Balasuriya UBR, Lee C-K, Zoonotic encephalitides caused by arboviruses: transmission and epidemiology of alphaviruses and flaviviruses. Clin Exp Vaccine Res. 2014;3: 58–77. doi: 10.7774/cevr.2014.3.1.58 24427764
46. Couderc T, Chretien F, Schilte C, Disson O, Brigitte M, A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog. 2008.
47. Lukaszewski RA, Brooks TJ, Pegylated alpha interferon is an effective treatment for virulent venezuelan equine encephalitis virus and has profound effects on the host immune response to infection. Journal of Virology. 2000;74: 5006–5015. 10799574
48. Pinto AJ, Morahan PS, Brinton M, Stewart D, Gavin E, Comparative therapeutic efficacy of recombinant interferons-alpha, -beta, and -gamma against alphatogavirus, bunyavirus, flavivirus, and herpesvirus infections. J Interferon Res. 1990;10: 293–298. 1696607
49. White LK, Sali T, Alvarado D, Gatti E, Pierre P, Streblow D, et al. Chikungunya virus induces IPS-1-dependent innate immune activation and protein kinase R-independent translational shutoff. Journal of Virology. American Society for Microbiology; 2011;85: 606–620. doi: 10.1128/JVI.00767-10
50. Navarro L, Mowen K, Rodems S, Weaver B, Reich N, Spector D, et al. Cytomegalovirus activates interferon immediate-early response gene expression and an interferon regulatory factor 3-containing interferon-stimulated response element-binding complex. Mol Cell Biol. 1998;18: 3796–3802. 9632763
51. Defilippis VR, Robinson B, Keck TM, Hansen SG, Nelson JA, Früh KJ, Interferon regulatory factor 3 is necessary for induction of antiviral genes during human cytomegalovirus infection. Journal of Virology. American Society for Microbiology; 2006;80: 1032–1037. doi: 10.1128/JVI.80.2.1032-1037.2006
52. Defilippis VR, Sali T, Alvarado D, White L, Bresnahan W, Früh KJ, Activation of the interferon response by human cytomegalovirus occurs via cytoplasmic double-stranded DNA but not glycoprotein B. Journal of Virology. 2010;84: 8913–8925. doi: 10.1128/JVI.00169-10 20573816
53. Schneider WM, Chevillotte MD, Rice CM, Interferon-Stimulated Genes: A Complex Web of Host Defenses. Annu Rev Immunol. 2014;32: 513–545. doi: 10.1146/annurev-immunol-032713-120231 24555472
54. Maringer K, Fernandez-Sesma A, Message in a bottle: lessons learned from antagonism of STING signalling during RNA virus infection. Cytokine &Growth Factor Reviews. 2014;25: 669–679. doi: 10.1016/j.cytogfr.2014.08.004
55. Dai P, Wang W, Cao H, Avogadri F, Dai L, Drexler I, et al. Modified Vaccinia Virus Ankara Triggers Type I IFN Production in Murine Conventional Dendritic Cells via a cGAS/STING-Mediated Cytosolic DNA-Sensing Pathway. PLoS Pathog. 2014;10: e1003989. 24743339
56. Sanjana NE, Shalem O, Zhang F, Improved vectors and genome-wide libraries for CRISPR screening. Nat Meth. 2014;11: 783–784. doi: 10.1038/nmeth.3047
57. Sternberg SH, Haurwitz RE, Doudna JA, Mechanism of substrate selection by a highly specific CRISPR endoribonuclease. RNA. 2012;18: 661–672. doi: 10.1261/rna.030882.111 22345129
58. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science. American Association for the Advancement of Science; 2013;339: 823–826. doi: 10.1126/science.1232033
59. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F, Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8: 2281–2308. doi: 10.1038/nprot.2013.143 24157548
60. Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science. American Association for the Advancement of Science; 2006;314: 994–997. doi: 10.1126/science.1132505
61. Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell RA, et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proceedings of the National Academy of Sciences. National Acad Sciences; 2006;103: 8459–8464. doi: 10.1073/pnas.0603082103
62. Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, Röhl I, et al. cGAS produces a 2“-5-”linked cyclic dinucleotide second messenger that activates STING. Nature. 2013;498: 380–384. doi: 10.1038/nature12306 23722158
63. Burdette DL, Vance RE, STING and the innate immune response to nucleic acids in the cytosol. Nat Immunol. 2013;14: 19–26. doi: 10.1038/ni.2491 23238760
64. Gao P, Ascano M, Zillinger T, Wang W, Dai P, Serganov AA, et al. Structure-function analysis of STING activation by c[G(2',5')pA(3“,5”)p] and targeting by antiviral DMXAA. Cell. 2013;154: 748–762. doi: 10.1016/j.cell.2013.07.023 23910378
65. Prantner D, Perkins DJ, Lai W, Williams MS, Sharma S, Fitzgerald KA, et al. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J Biol Chem. 2012;287: 39776–39788. doi: 10.1074/jbc.M112.382986 23027866
66. Niesen FH, Berglund H, Vedadi M, The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc. 2007;2: 2212–2221. doi: 10.1038/nprot.2007.321 17853878
67. Zhang X, Shi H, Wu J, Zhang X, Sun L, Chen C, et al. Cyclic GMP-AMP Containing Mixed Phosphodiester Linkages IsAn Endogenous High-Affinity Ligand for STING. Molecular Cell. Elsevier Inc; 2013;51: 226–235. doi: 10.1016/j.molcel.2013.05.022
68. Liu S, Cai X, Wu J, Cong Q, Chen X, Li T, et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science. 2015;347: aaa2630–aaa2630. doi: 10.1126/science.aaa2630 25636800
69. Defilippis VR, Alvarado D, Sali T, Rothenburg S, Früh K, Human cytomegalovirus induces the interferon response via the DNA sensor ZBP1. Journal of Virology. 2010;84: 585–598. doi: 10.1128/JVI.01748-09 19846511
70. Parvatiyar K, Zhang Z, Teles RM, Ouyang S, Jiang Y, Iyer SS, et al. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nature Publishing Group. 2012;13: 1155–1161. doi: 10.1038/ni.2460
71. Motani K, Ito S, Nagata S, DNA-Mediated Cyclic GMP-AMP Synthase-Dependent and -Independent Regulation of Innate Immune Responses. J Immunol. American Association of Immunologists; 2015;194: 4914–4923. doi: 10.4049/jimmunol.1402705
72. Li Z, Liu G, Sun L, Teng Y, Guo X, Jia J, Feng P, et al. PPM1A Regulates Antiviral Signaling by Antagonizing TBK1-Mediated STING Phosphorylation and Aggregation. PLoS Pathog. 2015;11: e1004783–26. doi: 10.1371/journal.ppat.1004783 25815785
73. Zhang Z, Yuan B, Bao M, Lu N, Kim T, Liu Y-J, The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat Immunol. 2011;12: 959–965. doi: 10.1038/ni.2091 21892174
74. Jakobsen MR, Bak RO, Andersen A, Berg RK, Jensen SB, Jin T, et al. IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication. Proc Natl Acad Sci U S A. 2013. doi: 10.1073/pnas.1311669110
75. Mankan AK, Schmidt T, Chauhan D, Goldeck M, Honing K, Gaidt M, et al. Cytosolic RNA:DNA hybrids activate the cGAS-STING axis. The EMBO Journal. 2014. doi: 10.15252/embj.201488726
76. Sun C, Schattgen SA, Pisitkun P, Jorgensen JP, Hilterbrand AT, Wang LJ, et al. Evasion of Innate Cytosolic DNA Sensing by a Gammaherpesvirus Facilitates Establishment of Latent Infection. The Journal of Immunology. 2015;194: 1819–1831. doi: 10.4049/jimmunol.1402495 25595793
77. Panchanathan R, Liu H, Xin D, Choubey D, Identification of a negative feedback loop between cyclic di-GMP-induced levels of IFI16 and p202 cytosolic DNA sensors and STING. Innate Immunity. 2014;20: 751–759. doi: 10.1177/1753425913507097 24131791
78. Hansen K, Prabakaran T, Laustsen A, Jorgensen SE, Rahbaek SH, Jensen SB, et al. Listeria monocytogenes induces IFN expression through an IFI16-, cGAS- and STING-dependent pathway. The EMBO Journal. 2014;33: 1654–1666. doi: 10.15252/embj.201488029 24970844
79. Grandvaux N, Servant MJ, Tenoever B, Sen GC, Balachandran S, Barber GN, et al. Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. Journal of Virology. 2002;76: 5532–5539. 11991981
80. Elco CP, Guenther JM, Williams BRG, Sen GC, Analysis of genes induced by Sendai virus infection of mutant cell lines reveals essential roles of interferon regulatory factor 3, NF-kappaB, and interferon but not toll-like receptor 3. Journal of Virology. American Society for Microbiology; 2005;79: 3920–3929. doi: 10.1128/JVI.79.7.3920-3929.2005
81. Noyce RS, Collins SE, Mossman KL, Identification of a novel pathway essential for the immediate-early, interferon-independent antiviral response to enveloped virions. Journal of Virology. American Society for Microbiology; 2006;80: 226–235. doi: 10.1128/JVI.80.1.226-235.2006
82. Noyce RS, Collins SE, Mossman KL, Identification of a novel pathway essential for the immediate-early, interferon-independent antiviral response to enveloped virions. Journal of Virology. American Society for Microbiology; 2006;80: 226–235. doi: 10.1128/JVI.80.1.226-235.2006
83. Abdul-Sater AA, Majoros A, Plumlee CR, Perry S, Gu AD, Lee C, et al. Different STAT Transcription Complexes Drive Early and Delayed Responses to Type I IFNs. The Journal of Immunology. 2015;195: 210–216. doi: 10.4049/jimmunol.1401139 26019270
84. Blaszczyk K, Olejnik A, Nowicka H, Ozgyin L, Chen Y-L, Chmielewski S, et al. STAT2/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1. Biochem J. Portland Press Ltd; 2015;466: 511–524. doi: 10.1042/BJ20140644
85. Sarkis PTN, Ying S, Xu R, Yu X-F, STAT1-independent cell type-specific regulation of antiviral APOBEC3G by IFN-alpha. The Journal of Immunology. 2006;177: 4530–4540. 16982890
86. Hahm B, Trifilo MJ, Zuniga EI, Oldstone MBA, Viruses Evade the Immune System through Type I Interferon-Mediated STAT2-Dependent, but STAT1-Independent, Signaling. Immunity. 2005;22: 247–257. doi: 10.1016/j.immuni.2005.01.005 15723812
87. Ousman SS, Wang J, Campbell IL, Differential Regulation of Interferon Regulatory Factor (IRF)-7 and IRF-9 Gene Expression in the Central Nervous System during Viral Infection. Journal of Virology. 2005;79: 7514–7527. doi: 10.1128/JVI.79.12.7514-7527.2005 15919906
88. Cao Z, Baguley BC, Ching LM, Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res. 2001;61: 1517–1521. 11245459
89. Tang CK, Aoshi T, Jounai N, Ito J, Ohata K, Kobiyama K, et al. The Chemotherapeutic Agent DMXAA as a Unique IRF3-Dependent Type-2 Vaccine Adjuvant. PLoS ONE. 2013;8: e60038. doi: 10.1371/journal.pone.0060038.g003 23555875
90. Guo F, Han Y, Zhao X, Wang J, Liu F, Xu C, et al. STING Agonists Induce an Innate Antiviral Immune Response against Hepatitis B Virus. Antimicrobial Agents and Chemotherapy. 2015;59: 1273–1281. doi: 10.1128/AAC.04321-14 25512416
91. Ziegler SA, Lu L, da Rosa APAT, Xiao S-Y, Tesh RB, An animal model for studying the pathogenesis of chikungunya virus infection. Am J Trop Med Hyg. 2008;79: 133–139. 18606777
92. Gardner J, Anraku I, Le TT, Larcher T, Major L, Roques P, et al. Chikungunya Virus Arthritis in Adult Wild-Type Mice. Journal of Virology. 2010;84: 8021–8032. doi: 10.1128/JVI.02603-09 20519386
93. Morrison TE, Oko L, Montgomery SA, Whitmore AC, Lotstein AR, Gunn BM, et al. A Mouse Model of Chikungunya Virus—Induced Musculoskeletal Inflammatory Disease. AJPA. Elsevier Inc; 2011;178: 32–40. doi: 10.1016/j.ajpath.2010.11.018
94. Hawman DW, Stoermer KA, Montgomery SA, Pal P, Oko L, Diamond MS, et al. Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response. Journal of Virology. 2013;87: 13878–13888. doi: 10.1128/JVI.02666-13 24131709
95. Taylor JL, Schoenherr C, Grossberg SE, Protection against Japanese encephalitis virus in mice and hamsters by treatment with carboxymethylacridanone, a potent interferon inducer. J Infect Dis. Oxford University Press; 1980;142: 394–399.
96. Dubensky TW, Kanne DB, Leong ML, Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants. Ther Adv Vaccines. 2013;1: 131–143. doi: 10.1177/2051013613501988 24757520
97. Li X-D, Wu J, Gao D, Wang H, Sun L, Chen ZJ, Pivotal Roles of cGAS-cGAMP Signaling in Antiviral Defense and Immune Adjuvant Effects. Science. American Association for the Advancement of Science; 2013;341: 1390–1394. doi: 10.1126/science.1244040
98. Hanson MC, Crespo MP, Abraham W, Moynihan KD, Szeto GL, Chen SH, et al. Nanoparticulate STING agonists are potent lymph node—targeted vaccine adjuvants. J Clin Invest. 2015;125: 2532–2546. doi: 10.1172/JCI79915 25938786
99. Peng S, Monie A, Pang X, Hung C-F, Wu TC, Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines. J Biomed Sci. BioMed Central Ltd; 2011;18: 21. doi: 10.1186/1423-0127-18-21
100. Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC, Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid. British Journal of Cancer. 2002;86: 1937–1942. doi: 10.1038/sj.bjc.6600368 12085190
101. Baguley BC, Ching L-M, DMXAA: an antivascular agent with multiple host responses. Int J Radiat Oncol Biol Phys. 2002;54: 1503–1511. 12459378
102. DiDonato JA, Mercurio F, Karin M, NF-κB and the link between inflammation and cancer. Immunol Rev. 2012;246: 379–400. doi: 10.1111/j.1600-065X.2012.01099.x 22435567
103. Tornatore L, Thotakura AK, Bennett J, Moretti M, Franzoso G, The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation. Trends in Cell Biology. 2012;22: 557–566. doi: 10.1016/j.tcb.2012.08.001 22995730
104. Bartlett NW, Slater L, Glanville N, Haas JJ, Caramori G, Casolari P, et al. Defining critical roles for NF-κB p65 and type I interferon in innate immunity to rhinovirus. EMBO Mol Med. 2012;4: 1244–1260. doi: 10.1002/emmm.201201650 23165884
105. Falvo JV, Parekh BS, Lin CH, Fraenkel E, Maniatis T, Assembly of a Functional Beta Interferon Enhanceosome Is Dependent on ATF-2-c-jun Heterodimer Orientation. Mol Cell Biol. 2000;20: 4814–4825. doi: 10.1128/MCB.20.13.4814-4825.2000 10848607
106. Wang J, Basagoudanavar SH, Wang X, Hopewell E, Albrecht R, Garcia-Sastre A, et al. NF- B RelA Subunit Is Crucial for Early IFN- Expression and Resistance to RNA Virus Replication. The Journal of Immunology. 2010;185: 1720–1729. doi: 10.4049/jimmunol.1000114 20610653
107. Panne D, Maniatis T, Harrison SC, An atomic model of the interferon-beta enhanceosome. Cell. 2007;129: 1111–1123. doi: 10.1016/j.cell.2007.05.019 17574024
108. Horan KA, Hansen K, Jakobsen MR, Holm CK, Soby S, Unterholzner L, et al. Proteasomal Degradation of Herpes Simplex Virus Capsids in Macrophages Releases DNA to the Cytosol for Recognition by DNA Sensors. The Journal of Immunology. 2013;190: 2311–2319. doi: 10.4049/jimmunol.1202749 23345332
109. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews. Elsevier; 2012.
110. Hahm B, Trifilo MJ, Zuniga EI, Oldstone MBA, Viruses Evade the Immune System through Type I Interferon-Mediated STAT2-Dependent, but STAT1-Independent, Signaling. Immunity. 2005;22: 247–257. doi: 10.1016/j.immuni.2005.01.005 15723812
111. Ousman SS, Wang J, Campbell IL, Differential regulation of interferon regulatory factor (IRF)-7 and IRF-9 gene expression in the central nervous system during viral infection. Journal of Virology. American Society for Microbiology; 2005;79: 7514–7527. doi: 10.1128/JVI.79.12.7514-7527.2005
112. Brierley MM, Fish EN, Stats: multifaceted regulators of transcription. Journal of Interferon & Cytokine Research. 2005;25: 733–744. doi: 10.1089/jir.2005.25.733
113. Hilkens CMU, Schlaak JF, Kerr IM, Differential responses to IFN-alpha subtypes in human T cells and dendritic cells. The Journal of Immunology. 2003;171: 5255–5263. 14607926
114. Moll HP, Maier T, Zommer A, Lavoie T, Brostjan C, The differential activity of interferon-α subtypes is consistent among distinct target genes and cell types. Cytokine. 2011;53: 52–59. doi: 10.1016/j.cyto.2010.09.006 20943413
115. Arnold-Schrauf C, Berod L, Sparwasser T, Dendritic cell specific targeting of MyD88 signalling pathways in vivo. Eur J Immunol. 2015;45: 32–39. doi: 10.1002/eji.201444747 25403892
116. Heiber JF, Barber GN, Evaluation of innate immune signaling pathways in transformed cells. Methods Mol Biol. 2012;797: 217. doi: 10.1007/978-1-61779-340-0_15 21948479
117. Hoarau JJ, Jaffar-Bandjee MC, Krejbich-Trotot P, Das T, Li-Pat-Yuen G, Dassa B, et al. Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. The Journal of Immunology. 2010;184: 5914–5927. doi: 10.4049/jimmunol.0900255 20404278
118. Botto S, Streblow DN, DeFilippis V, White L, Kreklywich CN, Smith PP, et al. IL-6 in human cytomegalovirus secretome promotes angiogenesis and survival of endothelial cells through the stimulation of survivin. Blood. 2011;117: 352–361. doi: 10.1182/blood-2010-06-291245 20930069
119. Hirsch AJ, Medigeshi GR, Meyers HL, DeFilippis V, Früh K, Briese T, et al. The Src family kinase c-Yes is required for maturation of West Nile virus particles. Journal of Virology. 2005;79: 11943–11951. doi: 10.1128/JVI.79.18.11943-11951.2005 16140770
120. Alzhanova D, Edwards DM, Hammarlund E, Scholz IG, Horst D, Wagner MJ, et al. Cowpox virus inhibits the transporter associated with antigen processing to evade T cell recognition. Cell Host and Microbe. Elsevier; 2009;6: 433–445. doi: 10.1016/j.chom.2009.09.013
121. Livak KJ, Schmittgen TD, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25: 402–408. doi: 10.1006/meth.2001.1262 11846609
122. DeFilippis V, Früh K, Rhesus cytomegalovirus particles prevent activation of interferon regulatory factor 3. Journal of Virology. American Society for Microbiology; 2005;79: 6419–6431. doi: 10.1128/JVI.79.10.6419-6431.2005